Physician profile
Omeralfaroug A Adam
NPI 1649700857
$124,359.31
in general payments reported to CMS, 2019-2025
10 companies · $121K in 2025
The $121K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $15.28 · 2021: $125 · 2022: $215 · 2023: $118 · 2024: $2,864 · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $119K · Travel and Lodging: $2,657 · Food and Beverage: $2,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $118,840.03 |
| Travel and Lodging | $2,656.82 |
| Food and Beverage | $2,370.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $60,775.22 | 2024-2025 | Qdot Micro Catheter, Nuvision Ice Catheter |
| Boston Scientific Corporation | $25,426.21 | 2023-2025 | Emblem Mri S-Icd, General - Therapies, Avvigo Guidance System |
| Abbott Laboratories | $21,541.18 | 2024-2025 | Assurity, Tacticath, Ensite Precision |
| Medtronic, INC. | $15,295.65 | 2022-2025 | Affera Mapping System, Attain Command + Surevalve |
| Biotronik INC. | $871.88 | 2025 | |
| Baxter Healthcare | $149.34 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Glaxosmithkline, LLC. | $120.55 | 2019 | |
| Amgen INC. | $31.61 | 2019-2020 | |
| Cordis US Corp. | $22.67 | 2024 | Mynx Venous Vcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omeralfaroug Adam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.